Abstract:Background/Aims: Accumulating evidence revealed that microRNAs (miRNAs) have been demonstrated as critical molecules in tumor development and progression. MiR-26a, located in a fragile chromosomal region associated with various human cancer, has been reported to be involved in regulating various cellular process, such as proliferation, apoptosis and invasion through targeting multiple oncogene. Docetaxel-mediated chemotherapy has been applied in improving the survival and prognosis of patients with advanced lung adenocarcinoma (LAD). However, chemoresistance remains a major impediment to clinical application of this agent. It has been presented that decreased miR-26a expression lead to cisplatin resistance and promoted growth and migration in human lung cancer. Enhancer of zeste homolog 2 (EZH2) is the target of miR-26a. The present study aimed to investigate the function of miR-26a/EZH2 in the acquisition of malignant behaviors of LAD. Methods: MiR-26a and EZH2 expression levels in the dcetaxel-insensitive groups (n = 19) and the docetaxel-sensitive groups (n = 18) were assessed by qRT-PCR. Colony formation assay, flow cytometric analysis, wound healing assay, cell transwell assays and western blotting were performed to assess the effects of miR-26a on proliferation, apoptosis and epithelial-to-mesenchymal (EMT) phenotypes in docetaxel resistant LAD cells in vitro. Xenograft transplantation, immunohistochemistry, tunel assays and western blotting assays were employed to demonstrate the role of miR-26a in docetaxel resistant LAD cells in vivo. The expression level of EZH2 in docetaxel-resistant LAD cells and corresponding parental cells was detected by qRT-PCR and western blotting. The relationship between miR-26a and EZH2 was confirmed by luciferase reporter assay. And rescue assays were performed to further confirm that miRNA-26a contributes to the acquisition of malignant behaviors of docetaxel-resistant LAD cells through targeting EZH2. Results: MiR-26a was significantly down-regulated in the dcetaxel-insensitive groups (n = 19) compared with the docetaxel-sensitive groups (n = 18) assessed by qRT-PCR. MiR-26a decreased the proliferation, increased the apoptosis rate and reversed EMT to MET of docetaxel-resistant LAD cells both in vivo and vitro. EZH2 was confirmed as target of miR-26a. Rescue assays further verified that the function of miR-26a exerts in docetaxel-resistant LAD cells is through targeting EZH2. Conclusions: Our data revealed that overexpression of miR-26a in docetaxel-resistant LAD cells could decrease the proliferation, increase the apoptosis rate and reverse EMT to MET of docetaxel-resistant LAD cells both in vivo and vitro and such function is partially exerted via downregulating EZH2. MiR-26a/EZH2 signal pathway makes contribute to the malignant phenotype of docetaxel-resistant of LAD cells which indicated that miR-26a exerts pivotal functions in the molecular etiology of chemoresistant lung adenocarcinoma.

Inhibition of ZEB1 Reverses EMT and Chemoresistance in Docetaxel-Resistant Human Lung Adenocarcinoma Cell Line.

Epithelial-mesenchymal Transition Contributes to Docetaxel Resistance in Human Non-Small Cell Lung Cancer.

ZEB1 Promotes Oxaliplatin Resistance Through the Induction of Epithelial - Mesenchymal Transition in Colon Cancer Cells

Epithelial - mesenchymal transition contributes to human non - small lung cancer cell line A549 docetaxel resistance

MicroRNA-451 Induces Epithelial–mesenchymal Transition in Docetaxel-Resistant Lung Adenocarcinoma Cells by Targeting Proto-Oncogene C-Myc

Long Noncoding RNA CCAT1 Acts As an Oncogene and Promotes Chemoresistance in Docetaxel-Resistant Lung Adenocarcinoma Cells.

Long Noncoding Rna Ror Regulates Chemoresistance In Docetaxel-Resistant Lung Adenocarcinoma Cells Via Epithelial Mesenchymal Transition Pathway

Establishment and Characterization of a Docetaxel-Resistant Variant of Human Lung Adenocarcinoma Cell Line SPC-A1

Nimotuzumab increases chemosensitivity of human lung adenocarcinoma cell lines to docetaxel.

MicroRNA-200b reverses chemoresistance of docetaxel-resistant human lung adenocarcinoma cells by targeting E2F3.

HMGB1-mediated autophagy promotes docetaxel resistance in human lung adenocarcinoma

Inactivation of Endothelial ZEB1 Impedes Tumor Progression and Sensitizes Tumors to Conventional Therapies.

CNTN-1 promotes docetaxel resistance and epithelial-to-mesenchymal transition via the PI3K/Akt signaling pathway in prostate cancer

MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells Through Targeting EZH2

Mechanism of Drug Resistance Identified in Human Lung Adenocarcinoma Cell Line SPC-A1 Selected for Resistance to Docetaxel

lncCRLA Enhanced&nbsp;Chemoresistance in Lung Adenocarcinoma That Underwentepithelial-mesenchymal Transition

Identification of ING 4 ( Inhibitor of Growth 4 ) as a Modulator of Docetaxel Sensitivity in Human Lung Adenocarcinoma

Research on the Mechanisms of Docetaxel-Resistant Human Lung Adenocarcinoma

Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt/β-Catenin activity and cancer stemness

ZEB1 potentiates chemoresistance in breast cancer stem cells by evading apoptosis

Epigenetic Downregulation of Runx3 by Dna Methylation Induces Docetaxel Chemoresistance in Human Lung Adenocarcinoma Cells by Activation of the Akt Pathway